Abstract
Abstract
Background
Since 2022, patients with five or more medicines are eligible for a medication review (MR) in a community pharmacy remunerated by the German health system. However, implementation has been slow, with few pharmacies providing MRs. Stakeholders’ input is necessary to detail how implementation strategies can be executed effectively on a national level. Prior research identified “external facilitation” and “altering incentives” as crucial strategies to achieve implementation outcomes.
Aim
To gather stakeholders’ recommendations for, and obtain consensus on, mechanisms of change that allow implementation strategies to work in practice.
Method
The consensus method used was the nominal group technique (NGT) with NGT-discussions held separately with pharmacy owners and pharmacy chambers employees. Votes were summed and the relative importance (rI) calculated, defined as (score achieved for a mechanism)/(maximum possible score) × 100. Content analysis provided context for the highest ranked mechanisms and allowed linking to implementation outcomes.
Results
Four NGT-discussions were held in 2023 (n = 2 owners; n = 2 chamber employees) with a total of 17 participants. The overall highest ranked mechanisms were fit-for-purpose software (rI = 154.7) detailed process support (rI = 104.9) and an expert support line (rI = 77.7). These together with financial viability (rI = 40.0) were prioritised by both participant groups. Three mechanisms were favoured for both implementation strategies, namely software, process support and materials (rI = 34.3).
Conclusion
This study identified stakeholders’ priorities for mechanisms of change to implement MRs in community pharmacies. Focusing efforts on the prioritised mechanisms is likely to significantly advance a national implementation plan for countries which are at an early implementation stage.
Funder
University of Innsbruck and Medical University of Innsbruck
Publisher
Springer Science and Business Media LLC
Reference60 articles.
1. World Health Organization. Medication safety in polypharmacy. World Health Organization. Geneva, Switzerland; 2019.
2. Varghese D, Ishida C, Koya HH. Polypharmacy. Stat Pearls. 2022. p. 1–9. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532953/. Accessed 29 Oct 2023.
3. Pazan F, Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur Geriatr Med. 2021;12(3):443–52.
4. Mair A, Fernandez-Llimos F, Alonso A, et al. Polypharmacy management by 2030: a patient safety challenge. Edinburgh: SIMPATHY Consortium; 2017.
5. Hall NJ, Donovan G, Wilkes S. A qualitative synthesis of pharmacist, other health professional and lay perspectives on the role of community pharmacy in facilitating care for people with long-term conditions. Res Social Adm Pharm. 2018;14(11):1043–57.